Zevalin

Zevalin is a CD20-directed, radiotherapeutic antibody indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell Non-Hodgkin's Lymphoma, including patients with rituximab refractory follicular Non-Hodgkin's Lymphoma.

IBA Molecular compounds and delivers the In-111 Zevalin and Y-90 Zevalin as part of the Zevalin therapeutic regimen.

For full prescribing and product information visit http://www.zevalin.com

To discuss availability, please contact your IBA Representative.